Psilocybin Spurs Brain Activity in Patients With Depression, Small Study Shows
The chemical derived from psychedelic mushrooms helped alleviate symptoms of depression and generated detectable neural responses that lasted weeks.
On Day 100, Mayor Adams Has Covid-19
Eric Adams tested positive after a series of public events promoting his first 100 days as mayor. He reminded eligible New Yorkers to take antivirals.
Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trials
Officials cited data showing the new Alzheimer’s drug has serious safety risks and may not help patients.
In India, Parents of Children with Rare Disease Plea for Help Online
India makes many of the world’s drugs, but treatments for rare diseases like spinal muscular atrophy are imported and prohibitively costly. In desperation, parents are raising funds on social media.
Inside a Campaign to Get Medicare Coverage for a New Alzheimer’s Drug
The Alzheimer’s Association has pushed relentlessly to get broad access to Aduhelm, despite safety risks and uncertain evidence that it helps patients.
The F.D.A. Suspends Use of Glaxo Antibody Drug in the U.S.
Manufacturers said lab testing revealed that the authorized dosage of the drug was not sufficiently potent against BA.2.
Call for more information
888-531-0245
info@siii-clinical.com
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.